Suchergebnisse - "Hanley, Michael J"

PubPharm (7)

1

Clinical Pharmacology of Brigatinib : A Next-Generation Anaplastic Lymphoma Kinase Inhibitor

enthalten in: Clinical pharmacokinetics | 2023

von Gupta, N. | Hanley, M. | Griffin, R. | +3

2

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

enthalten in: Journal of clinical pharmacology | 2023

von Hanley, M. | D'Arcangelo, M. | Felip, E. | +5

3

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer

enthalten in: British journal of clinical pharmacology | 2022

von Gupta, N. | Hanley, M. | Sinha, V.

CommentOn: Br J Clin Pharmacol. 2022 Feb;88(4):1930-1934. - PMID 34545619

4

Population pharmacokinetic and exposure-response analyses from ALTA-1L : Model-based analyses supporting the brigatinib dose in ALK-positive NSCLC

enthalten in: Clinical and translational science | 2022

von Gupta, N. | Reckamp, K. | Camidge, D. | +8

5

Effect of severe renal impairment on the pharmacokinetics of brigatinib

enthalten in: Investigational new drugs | 2021

von Gupta, N. | Hanley, M. | Kerstein, D. | +4

6

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer : Second Interim Analysis of the Phase III ALTA-1L Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Camidge, D. | Kim, H. | Ahn, M. | +19

CommentIn: J Clin Oncol. 2020 Nov 1;38(31):3581-3583. - PMID 32897826

7

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers

enthalten in: Clinical pharmacology in drug development | 2020

von Tugnait, M. | Gupta, N. | Hanley, M. | +5

1
[1]